Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nanrilkefusp Alfa - SOTIO

Next Previous
Drug Profile

Nanrilkefusp Alfa - SOTIO

Alternative Names: CYP 0150; CYP 0150 (RLI); IL-15-IL-15 receptor α fusion protein; Interleukin-15-interleukin-15 receptor alpha fusion protein; RLI; RLI 15; SO-C101; SOT-101; Super IL-15 cytokine

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytune Pharma
  • Developer SOTIO
  • Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin-15 receptor agonists; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Colorectal cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 13 Oct 2023 Nanrilkefusp Alfa is available for licensing as of 13 Oct 2023. https://sotio.com/contacts/sotio-eu
  • 13 Oct 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in France, Spain, USA, Czech Republic (SC)
  • 13 Oct 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in Czech Republic (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top